The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA).
Edgar Ben-Josef
No relevant relationships to disclose
Katherine Guthrie
No relevant relationships to disclose
Anthony B. El-Khoueiry
No relevant relationships to disclose
Christopher L. Corless
No relevant relationships to disclose
Mark Zalupski
No relevant relationships to disclose
Andrew M. Lowy
No relevant relationships to disclose
Charles R. Thomas
No relevant relationships to disclose
Steven R. Alberts
No relevant relationships to disclose
Laura A. Dawson
Research Funding - Bayer
Kenneth C. Micetich
No relevant relationships to disclose
Melanie B. Thomas
No relevant relationships to disclose
Abby B. Siegel
No relevant relationships to disclose
Charles David Blanke
No relevant relationships to disclose